Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25376349 | 0.98 | MAPT (0.83) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Hydrochloric Acid SCHEMBL27500997 | 0.96 | ADRA2A (0.76) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL41537 | 0.91 | ADRA2A (1.00) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL41536 | 0.89 | MAPT (1.00) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL21356923 | 0.89 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL16320883 | 0.89 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL1643328 | 0.89 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL2821312 | 0.89 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL2690356 | 0.89 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| SCHEMBL28047745 | 0.88 | ADRA2A (0.69) | ADRA2AADRA1AMAPTBLMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250059446-A1 | MULTIVALENT IONIC LIQUIDS AS PROCESS AIDS FOR BITUMEN EXTRACTION | STERLING SPECIALTY CHEMICALS HOLDING UK LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| EP-4346446-A1 | NUTRITIONAL COMPOSITIONS FOR SKELETAL MUSCLE | Mitocholine Ltd (GB) | 2024-04-10 | — | — | EP | claimed |
| US-20240108571-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | Slayback Pharma LLC. (US) | 2024-04-04 | — | — | US | claimed |
| CN-117715539-A | Skeletal muscle nutritional compositions | 米拓克兰有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2024040141-A1 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | RMJ HOLDINGS, LLC (US) | 2024-02-22 | — | — | WO | claimed |
| US-20240058376-A1 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | RMJH Holdings, LLC (US) | 2024-02-22 | — | — | US | claimed |
| US-11872305-B2 | Stable pharmaceutical compositions of succinylcholine chloride | AZURITY PHARMACEUTICALS, INC. | 2024-01-16 | — | — | US | claimed |
| WO-2023174433-A1 | SOLID, SEMISOLID, OR LIQUID COMPOSITIONS FOR AUGMENTING THE STABILITY, PERMEABILITY AND BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL SUBSTANCES | Smart Pharmaceutical (Suzhou) Co., Ltd. (CN) | 2023-09-21 | — | — | WO | claimed |
| US-11712449-B1 | Composition of matter, system, and method for enhanced magnesium uptake, retention, and synergistic actions | RMJH Holdings, LLC (US) | 2023-08-01 | — | — | US | claimed |
| EP-2079762-B1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS AND THEIR USE | CHEMIGATE OY (FI) | 2012-10-03 | — | — | EP | claimed |
| CN-102670592-A | Motherwort alkaloid and choline medicinal composition | CHENGDU NO 1 PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | claimed |
| US-20090270606-A1 | Process for the Preparation of Hydroxy Polymer Esters and Their Use | CHEMIGATE OY (FI) | 2009-10-29 | — | — | US | claimed |
| EP-2079762-A1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS AND THEIR USE | Ciba Holding Inc. (CH) | 2009-07-22 | — | — | EP | claimed |
| EP-1629016-B1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS | CIBA HOLDING INC (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007065681-A1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS AND THEIR USE | CIBA HOLDING INC. (CH) | 2007-06-14 | — | — | WO | claimed |
| US-20070009464-A1 | Process for the preparation of hydroxy polymer esters and their use | CHEMIGATE OY (FI) | 2007-01-11 | — | — | US | claimed |
| EP-1629016-A1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS AND THEIR USE | Ciba Specialty Chemicals Holding Inc. (CH) | 2006-03-01 | — | — | EP | claimed |
| WO-2004104048-A1 | A PROCESS FOR THE PREPARATION OF HYDROXY POLYMER ESTERS AND THEIR USE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-12-02 | — | — | WO | claimed |
| CN-1452482-A | Synergistic composition containing choline and succinic acid for treating insulin resistance and diabetes | VERTELETSKY PAVEL VASILIEVICH (RU) | 2003-10-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108571-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | CPT1B, ASS1, CPS1 | ADRA2A 447/4885ADRA1A 322/4885MAPT 3316/4885 |
| US-11872305-B2 | Stable pharmaceutical compositions of succinylcholine chloride | CPT1B, ASS1, CPS1 | ADRA2A 447/4885ADRA1A 322/4885MAPT 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.